Business Context and Reporting Period
This Form 8-K is a current report filed by TRxADE HEALTH, INC. (also referenced as TRXADE GROUP, INC. in the signature block) on August 6, 2021. The filing discloses the entry into a material definitive agreement and updates regarding a share repurchase program. The company is an emerging growth company with common stock (Symbol: MEDS) listed on the Nasdaq Capital Market.
Key Financial Metrics and Agreements
- Equity Offering: Entered into an Equity Distribution Agreement with EF Hutton to sell up to $9,000,000 of common stock via "at-the-market" offerings.
- Compensation: The sales agent will receive a commission of 2.0% of the gross sales price.
- Expense Reimbursement: The company agreed to reimburse the agent for specified expenses up to $50,000.
- Use of Proceeds: Net proceeds are intended for general corporate purposes, including working capital and capital expenditures.
- Share Repurchase Program: A previously authorized program to repurchase up to $1,000,000 of common stock was paused on August 5, 2021.
- Financial Performance: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Capital Raising: Initiated a new mechanism to raise capital through an "at-the-market" offering, subject to limitations under General Instruction I.B.6 of Form S-3 and the company's public float.
- Repurchase Suspension: The Board of Directors elected to pause the $1 million share repurchase program (authorized May 27, 2021) for the duration of the new equity offering. No shares had been repurchased under the program prior to the pause.
Guidance, Outlook, and Risks
- Flexibility: The company has no obligation to sell any shares under the new agreement and may suspend sales at any time. The agreement terminates upon the sale of all placement shares or earlier termination.
- Regulatory Constraints: Sales are limited by the company's public float and the number of authorized unissued shares available.
- Legal Disclaimers: The filing includes standard disclaimers that representations and warranties in the agreement are for the benefit of the agent and should not be relied upon as characterizations of the company's actual state of facts.
Investor Verification Checklist
- Verify the current number of authorized and unissued shares to assess the actual capacity for the $9 million offering.
- Confirm the company's current public float to understand the specific limitations under Form S-3 General Instruction I.B.6.
- Monitor future filings for actual sales volumes and proceeds generated under the Equity Distribution Agreement.
- Review the company's most recent 10-Q or 10-K for actual financial performance metrics (revenue, cash flow, debt) as this 8-K does not contain them.
- Check for any subsequent announcements regarding the resumption of the share repurchase program.